MORC2

Across TCGA pan-cancer cohorts, MORC2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MORC2 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MORC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MORC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

THYM, UCEC, and KICH are the cancer types where MORC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	All	0.673	0.983	<.001	36	view →
UCEC	DFS	Median	II,III,IV	0.922	0.439	.030	16	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	OS	Median	All	0.298	0.685	.016	12	view →
SARC	OS	Median	All	0.224	0.839	<.001	6	view →
COAD	OS	Median	III,IV	0.168	0.691	.041	6	view →
SKCM	OS	Median	II,III,IV	0.581	0.305	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MORC2–THYM (OS)

Open the THYM breakdown →